Skip to main content
Erschienen in: Pediatric Nephrology 2/2013

01.02.2013 | Original Article

Rituximab in post-transplant pediatric recurrent focal segmental glomerulosclerosis

verfasst von: Juhi Kumar, Ibrahim F. Shatat, Amy L. Skversky, Robert P. Woroniecki, Marcela Del Rio, Eduardo M. Perelstein, Valerie L. Johnson, Shefali Mahesh

Erschienen in: Pediatric Nephrology | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

Focal segmental glomerulosclerosis (FSGS) recurs in 20–40 % of allografts. Plasmapheresis (TPE) has been one of the mainstays of treatment with variable results. Rituximab (RTX), a monoclonal antibody to the protein CD20, is being used for treatment of recurrent FSGS (recFSGS) but pediatric experience is limited.

Methods

We conducted a retrospective review of eight patients with recFSGS, treated with RTX (1–4 doses) after having minimal response to TPE. Complete response was defined as a decrease in urine protein creatinine ratio (Up/c) to less than 0.2 and partial response was a decrease in Up/c ratio by 50 % of baseline and in the sub-nephrotic range (U p/c <2).

Results

Complete response was seen in two of eight patients, and partial response was seen in four of eight patients. Two patients had no response. At last follow-up, all the partial responders had sub-nephrotic range proteinuria (Up/c ratios ranging from 0.29 to 1.6). Delayed response, up to 9 months post-RTX, was also seen in some of the patients. Significant complications such as rituximab-associated lung injury (RALI), acute tubular necrosis, and central nervous system(CNS) malignancy were also observed in our case series.

Conclusions

Rituximab can be used with caution as a treatment for recFSGS. Efficacy is variable from none to complete response. Even partial reduction in proteinuria is of benefit in prolonging the life of the allograft. Long-term, multicenter studies are needed to prove its sustained efficacy in those who respond and to monitor for serious adverse effects.
Literatur
1.
Zurück zum Zitat Kitiyakara C, Eggers P, Kopp JB (2004) Twenty-one-year trend in ESRD due to focal segmental glomerulosclerosis in the United States. Am J Kidney Dis 44:815–825PubMed Kitiyakara C, Eggers P, Kopp JB (2004) Twenty-one-year trend in ESRD due to focal segmental glomerulosclerosis in the United States. Am J Kidney Dis 44:815–825PubMed
2.
Zurück zum Zitat Schachter ME, Monahan M, Radhakrishnan J, Crew J, Pollak M, Ratner L, Valeri AM, Stokes MB, Appel GB (2010) Recurrent focal segmental glomerulosclerosis in the renal allograft: single center experience in the era of modern immunosuppression. Clin Nephrol 74:173–181PubMed Schachter ME, Monahan M, Radhakrishnan J, Crew J, Pollak M, Ratner L, Valeri AM, Stokes MB, Appel GB (2010) Recurrent focal segmental glomerulosclerosis in the renal allograft: single center experience in the era of modern immunosuppression. Clin Nephrol 74:173–181PubMed
3.
Zurück zum Zitat Tejani A, Stablein DH (1992) Recurrence of focal segmental glomerulosclerosis posttransplantation: a special report of the North American Pediatric Renal Transplant Cooperative Study. J Am Soc Nephrol 2:S258–S263PubMed Tejani A, Stablein DH (1992) Recurrence of focal segmental glomerulosclerosis posttransplantation: a special report of the North American Pediatric Renal Transplant Cooperative Study. J Am Soc Nephrol 2:S258–S263PubMed
4.
Zurück zum Zitat Dantal J, Godfrin Y, Koll R, Perretto S, Naulet J, Bouhours JF, Soulillou JP (1998) Antihuman immunoglobulin affinity immunoadsorption strongly decreases proteinuria in patients with relapsing nephrotic syndrome. J Am Soc Nephrol 9:1709–1715PubMed Dantal J, Godfrin Y, Koll R, Perretto S, Naulet J, Bouhours JF, Soulillou JP (1998) Antihuman immunoglobulin affinity immunoadsorption strongly decreases proteinuria in patients with relapsing nephrotic syndrome. J Am Soc Nephrol 9:1709–1715PubMed
5.
Zurück zum Zitat Iharada A, Kaneko K, Tsuji S, Hasui M, Kanda S, Nishiyama T (2009) Increased nitric oxide production by T- and B-cells in idiopathic nephrotic syndrome. Pediatr Nephrol 24:1033–1038PubMedCrossRef Iharada A, Kaneko K, Tsuji S, Hasui M, Kanda S, Nishiyama T (2009) Increased nitric oxide production by T- and B-cells in idiopathic nephrotic syndrome. Pediatr Nephrol 24:1033–1038PubMedCrossRef
6.
Zurück zum Zitat Benz K, Dotsch J, Rascher W, Stachel D (2004) Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr Nephrol 19:794–797PubMedCrossRef Benz K, Dotsch J, Rascher W, Stachel D (2004) Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr Nephrol 19:794–797PubMedCrossRef
7.
Zurück zum Zitat Nozu K, Iijima K, Fujisawa M, Nakagawa A, Yoshikawa N, Matsuo M (2005) Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome. Pediatr Nephrol 20:1660–1663PubMedCrossRef Nozu K, Iijima K, Fujisawa M, Nakagawa A, Yoshikawa N, Matsuo M (2005) Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome. Pediatr Nephrol 20:1660–1663PubMedCrossRef
8.
Zurück zum Zitat Pescovitz MD, Book BK, Sidner RA (2006) Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment. N Engl J Med 354:1961–1963PubMedCrossRef Pescovitz MD, Book BK, Sidner RA (2006) Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment. N Engl J Med 354:1961–1963PubMedCrossRef
9.
Zurück zum Zitat Apeland T, Hartmann A (2008) Rituximab therapy in early recurrent focal segmental sclerosis after renal transplantation. Nephrol Dial Transplant 23:2091–2094PubMedCrossRef Apeland T, Hartmann A (2008) Rituximab therapy in early recurrent focal segmental sclerosis after renal transplantation. Nephrol Dial Transplant 23:2091–2094PubMedCrossRef
10.
Zurück zum Zitat Bayrakci US, Baskin E, Sakalli H, Karakayali H, Haberal M (2009) Rituximab for post-transplant recurrences of FSGS. Pediatr Transplant 13:240–243PubMedCrossRef Bayrakci US, Baskin E, Sakalli H, Karakayali H, Haberal M (2009) Rituximab for post-transplant recurrences of FSGS. Pediatr Transplant 13:240–243PubMedCrossRef
11.
Zurück zum Zitat Dello Strologo L, Guzzo I, Laurenzi C, Vivarelli M, Parodi A, Barbano G, Camilla R, Scozzola F, Amore A, Ginevri F, Murer L (2009) Use of rituximab in focal glomerulosclerosis relapses after renal transplantation. Transplantation 88:417–420PubMedCrossRef Dello Strologo L, Guzzo I, Laurenzi C, Vivarelli M, Parodi A, Barbano G, Camilla R, Scozzola F, Amore A, Ginevri F, Murer L (2009) Use of rituximab in focal glomerulosclerosis relapses after renal transplantation. Transplantation 88:417–420PubMedCrossRef
12.
Zurück zum Zitat Grenda R, Jarmuzek W, Piatosa B, Rubik J (2011) Long-term effect of rituximab in maintaining remission of recurrent and plasmapheresis-dependent nephrotic syndrome post-renal transplantation—case report. Pediatr Transplant 15:E121–E125PubMedCrossRef Grenda R, Jarmuzek W, Piatosa B, Rubik J (2011) Long-term effect of rituximab in maintaining remission of recurrent and plasmapheresis-dependent nephrotic syndrome post-renal transplantation—case report. Pediatr Transplant 15:E121–E125PubMedCrossRef
13.
Zurück zum Zitat Hickson LJ, Gera M, Amer H, Iqbal CW, Moore TB, Milliner DS, Cosio FG, Larson TS, Stegall MD, Ishitani MB, Gloor JM, Griffin MD (2009) Kidney transplantation for primary focal segmental glomerulosclerosis: outcomes and response to therapy for recurrence. Transplantation 87:1232–1239PubMedCrossRef Hickson LJ, Gera M, Amer H, Iqbal CW, Moore TB, Milliner DS, Cosio FG, Larson TS, Stegall MD, Ishitani MB, Gloor JM, Griffin MD (2009) Kidney transplantation for primary focal segmental glomerulosclerosis: outcomes and response to therapy for recurrence. Transplantation 87:1232–1239PubMedCrossRef
14.
Zurück zum Zitat Nakayama M, Kamei K, Nozu K, Matsuoka K, Nakagawa A, Sako M, Iijima K (2008) Rituximab for refractory focal segmental glomerulosclerosis. Pediatr Nephrol 23:481–485PubMedCrossRef Nakayama M, Kamei K, Nozu K, Matsuoka K, Nakagawa A, Sako M, Iijima K (2008) Rituximab for refractory focal segmental glomerulosclerosis. Pediatr Nephrol 23:481–485PubMedCrossRef
15.
Zurück zum Zitat Vinai M, Waber P, Seikaly MG (2010) Recurrence of focal segmental glomerulosclerosis in renal allograft: an in-depth review. Pediatr Transplant 14:314–325PubMedCrossRef Vinai M, Waber P, Seikaly MG (2010) Recurrence of focal segmental glomerulosclerosis in renal allograft: an in-depth review. Pediatr Transplant 14:314–325PubMedCrossRef
16.
Zurück zum Zitat Baum MA (2004) Outcomes after renal transplantation for FSGS in children. Pediatr Transplant 8:329–333PubMedCrossRef Baum MA (2004) Outcomes after renal transplantation for FSGS in children. Pediatr Transplant 8:329–333PubMedCrossRef
17.
Zurück zum Zitat Schachter AD, Harmon WE (2001) Single-center analysis of early recurrence of nephrotic syndrome following renal transplantation in children. Pediatr Transplant 5:406–409PubMedCrossRef Schachter AD, Harmon WE (2001) Single-center analysis of early recurrence of nephrotic syndrome following renal transplantation in children. Pediatr Transplant 5:406–409PubMedCrossRef
18.
Zurück zum Zitat Ingulli E, Tejani A (1991) Incidence, treatment, and outcome of recurrent focal segmental glomerulosclerosis posttransplantation in 42 allografts in children–a single-center experience. Transplantation 51:401–405PubMedCrossRef Ingulli E, Tejani A (1991) Incidence, treatment, and outcome of recurrent focal segmental glomerulosclerosis posttransplantation in 42 allografts in children–a single-center experience. Transplantation 51:401–405PubMedCrossRef
19.
Zurück zum Zitat Baum MA, Stablein DM, Panzarino VM, Tejani A, Harmon WE, Alexander SR (2001) Loss of living donor renal allograft survival advantage in children with focal segmental glomerulosclerosis. Kidney Int 59:328–333PubMedCrossRef Baum MA, Stablein DM, Panzarino VM, Tejani A, Harmon WE, Alexander SR (2001) Loss of living donor renal allograft survival advantage in children with focal segmental glomerulosclerosis. Kidney Int 59:328–333PubMedCrossRef
20.
Zurück zum Zitat Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, Maiguel D, Karumanchi SA, Yap HK, Saleem M, Zhang Q, Nikolic B, Chaudhuri A, Daftarian P, Salido E, Torres A, Salifu M, Sarwal MM, Schaefer F, Morath C, Schwenger V, Zeier M, Gupta V, Roth D, Rastaldi MP, Burke G, Ruiz P, Reiser J (2011) Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 17:952–960PubMedCrossRef Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, Maiguel D, Karumanchi SA, Yap HK, Saleem M, Zhang Q, Nikolic B, Chaudhuri A, Daftarian P, Salido E, Torres A, Salifu M, Sarwal MM, Schaefer F, Morath C, Schwenger V, Zeier M, Gupta V, Roth D, Rastaldi MP, Burke G, Ruiz P, Reiser J (2011) Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 17:952–960PubMedCrossRef
21.
Zurück zum Zitat Dall’Amico R, Ghiggeri G, Carraro M, Artero M, Ghio L, Zamorani E, Zennaro C, Basile G, Montini G, Rivabella L, Cardillo M, Scalamogna M, Ginevri F (1999) Prediction and treatment of recurrent focal segmental glomerulosclerosis after renal transplantation in children. Am J Kidney Dis 34:1048–1055PubMedCrossRef Dall’Amico R, Ghiggeri G, Carraro M, Artero M, Ghio L, Zamorani E, Zennaro C, Basile G, Montini G, Rivabella L, Cardillo M, Scalamogna M, Ginevri F (1999) Prediction and treatment of recurrent focal segmental glomerulosclerosis after renal transplantation in children. Am J Kidney Dis 34:1048–1055PubMedCrossRef
22.
Zurück zum Zitat Mahesh S, Del Rio M, Feuerstein D, Greenstein S, Schechner R, Tellis V, Kaskel F (2008) Demographics and response to therapeutic plasma exchange in pediatric renal transplantation for focal glomerulosclerosis: a single center experience. Pediatr Transplant 12:682–688PubMedCrossRef Mahesh S, Del Rio M, Feuerstein D, Greenstein S, Schechner R, Tellis V, Kaskel F (2008) Demographics and response to therapeutic plasma exchange in pediatric renal transplantation for focal glomerulosclerosis: a single center experience. Pediatr Transplant 12:682–688PubMedCrossRef
23.
Zurück zum Zitat Pradhan M, Petro J, Palmer J, Meyers K, Baluarte HJ (2003) Early use of plasmapheresis for recurrent post-transplant FSGS. Pediatr Nephrol 18:934–938PubMedCrossRef Pradhan M, Petro J, Palmer J, Meyers K, Baluarte HJ (2003) Early use of plasmapheresis for recurrent post-transplant FSGS. Pediatr Nephrol 18:934–938PubMedCrossRef
24.
Zurück zum Zitat Kershaw DB, Sedman AB, Kelsch RC, Bunchman TE (1994) Recurrent focal segmental glomerulosclerosis in pediatric renal transplant recipients: successful treatment with oral cyclophosphamide. Clin Transplant 8:546–549PubMed Kershaw DB, Sedman AB, Kelsch RC, Bunchman TE (1994) Recurrent focal segmental glomerulosclerosis in pediatric renal transplant recipients: successful treatment with oral cyclophosphamide. Clin Transplant 8:546–549PubMed
25.
Zurück zum Zitat Raafat RH, Kalia A, Travis LB, Diven SC (2004) High-dose oral cyclosporin therapy for recurrent focal segmental glomerulosclerosis in children. Am J Kidney Dis 44:50–56PubMedCrossRef Raafat RH, Kalia A, Travis LB, Diven SC (2004) High-dose oral cyclosporin therapy for recurrent focal segmental glomerulosclerosis in children. Am J Kidney Dis 44:50–56PubMedCrossRef
26.
Zurück zum Zitat Fornoni A, Sageshima J, Wei C, Merscher-Gomez S, Aguillon-Prada R, Jauregui AN, Li J, Mattiazzi A, Ciancio G, Chen L, Zilleruelo G, Abitbol C, Chandar J, Seeherunvong W, Ricordi C, Ikehata M, Rastaldi MP, Reiser J, Burke GW 3rd (2011) Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med 3:85ra46PubMedCrossRef Fornoni A, Sageshima J, Wei C, Merscher-Gomez S, Aguillon-Prada R, Jauregui AN, Li J, Mattiazzi A, Ciancio G, Chen L, Zilleruelo G, Abitbol C, Chandar J, Seeherunvong W, Ricordi C, Ikehata M, Rastaldi MP, Reiser J, Burke GW 3rd (2011) Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med 3:85ra46PubMedCrossRef
27.
Zurück zum Zitat Tsagalis G, Psimenou E, Nakopoulou L, Laggouranis A (2011) Combination treatment with plasmapheresis and rituximab for recurrent focal segmental glomerulosclerosis after renal transplantation. Artif Organs 35:420–425PubMedCrossRef Tsagalis G, Psimenou E, Nakopoulou L, Laggouranis A (2011) Combination treatment with plasmapheresis and rituximab for recurrent focal segmental glomerulosclerosis after renal transplantation. Artif Organs 35:420–425PubMedCrossRef
28.
Zurück zum Zitat Hristea D, Hadaya K, Marangon N, Buhler L, Villard J, Morel P, Martin PY (2007) Successful treatment of recurrent focal segmental glomerulosclerosis after kidney transplantation by plasmapheresis and rituximab. Transpl Int 20:102–105PubMedCrossRef Hristea D, Hadaya K, Marangon N, Buhler L, Villard J, Morel P, Martin PY (2007) Successful treatment of recurrent focal segmental glomerulosclerosis after kidney transplantation by plasmapheresis and rituximab. Transpl Int 20:102–105PubMedCrossRef
29.
Zurück zum Zitat Kamar N, Faguer S, Esposito L, Guitard J, Nogier MB, Durand D, Rostaing L (2007) Treatment of focal segmental glomerular sclerosis with rituximab: 2 case reports. Clin Nephrol 67:250–254PubMed Kamar N, Faguer S, Esposito L, Guitard J, Nogier MB, Durand D, Rostaing L (2007) Treatment of focal segmental glomerular sclerosis with rituximab: 2 case reports. Clin Nephrol 67:250–254PubMed
30.
Zurück zum Zitat Gossmann J, Scheuermann EH, Porubsky S, Kachel HG, Geiger H, Hauser IA (2007) Abrogation of nephrotic proteinuria by rituximab treatment in a renal transplant patient with relapsed focal segmental glomerulosclerosis. Transpl Int 20:558–562PubMedCrossRef Gossmann J, Scheuermann EH, Porubsky S, Kachel HG, Geiger H, Hauser IA (2007) Abrogation of nephrotic proteinuria by rituximab treatment in a renal transplant patient with relapsed focal segmental glomerulosclerosis. Transpl Int 20:558–562PubMedCrossRef
31.
Zurück zum Zitat Meyer TN, Thaiss F, Stahl RA (2007) Immunoadsorbtion and rituximab therapy in a second living-related kidney transplant patient with recurrent focal segmental glomerulosclerosis. Transpl Int 20:1066–1071PubMedCrossRef Meyer TN, Thaiss F, Stahl RA (2007) Immunoadsorbtion and rituximab therapy in a second living-related kidney transplant patient with recurrent focal segmental glomerulosclerosis. Transpl Int 20:1066–1071PubMedCrossRef
32.
Zurück zum Zitat Yabu JM, Ho B, Scandling JD, Vincenti F (2008) Rituximab failed to improve nephrotic syndrome in renal transplant patients with recurrent focal segmental glomerulosclerosis. Am J Transplant 8:222–227PubMed Yabu JM, Ho B, Scandling JD, Vincenti F (2008) Rituximab failed to improve nephrotic syndrome in renal transplant patients with recurrent focal segmental glomerulosclerosis. Am J Transplant 8:222–227PubMed
33.
Zurück zum Zitat Sakai K, Takasu J, Nihei H, Yonekura T, Aoki Y, Kawamura T, Mizuiri S, Aikawa A (2010) Protocol biopsies for focal segmental glomerulosclerosis treated with plasma exchange and rituximab in a renal transplant patient. Clin Transplant 24(Suppl 22):60–65PubMedCrossRef Sakai K, Takasu J, Nihei H, Yonekura T, Aoki Y, Kawamura T, Mizuiri S, Aikawa A (2010) Protocol biopsies for focal segmental glomerulosclerosis treated with plasma exchange and rituximab in a renal transplant patient. Clin Transplant 24(Suppl 22):60–65PubMedCrossRef
34.
Zurück zum Zitat Rodriguez-Ferrero M, Ampuero J, Anaya F (2009) Rituximab and chronic plasmapheresis therapy of nephrotic syndrome in renal transplantation patients with recurrent focal segmental glomerulosclerosis. Transplant Proc 41:2406–2408PubMedCrossRef Rodriguez-Ferrero M, Ampuero J, Anaya F (2009) Rituximab and chronic plasmapheresis therapy of nephrotic syndrome in renal transplantation patients with recurrent focal segmental glomerulosclerosis. Transplant Proc 41:2406–2408PubMedCrossRef
35.
Zurück zum Zitat El-Firjani A, Hoar S, Karpinski J, Bell R, Deschenes MJ, Knoll GA (2008) Post-transplant focal segmental glomerulosclerosis refractory to plasmapheresis and rituximab therapy. Nephrol Dial Transplant 23:425PubMedCrossRef El-Firjani A, Hoar S, Karpinski J, Bell R, Deschenes MJ, Knoll GA (2008) Post-transplant focal segmental glomerulosclerosis refractory to plasmapheresis and rituximab therapy. Nephrol Dial Transplant 23:425PubMedCrossRef
36.
Zurück zum Zitat Freiberger V, Amann K, Heemann U, Frank H (2009) Effect of a triple blockade of the renin-angiotensin-system in recurrent focal segmental glomerulosclerosis after kidney transplantation. Transpl Int 22:1110–1113PubMedCrossRef Freiberger V, Amann K, Heemann U, Frank H (2009) Effect of a triple blockade of the renin-angiotensin-system in recurrent focal segmental glomerulosclerosis after kidney transplantation. Transpl Int 22:1110–1113PubMedCrossRef
37.
Zurück zum Zitat Sethna C, Benchimol C, Hotchkiss H, Frank R, Infante L, Vento S, Trachtman H (2011) Treatment of recurrent focal segmental glomerulosclerosis in pediatric kidney transplant recipients: effect of rituximab. J Transplant. doi:10.1155/2011/389542 PubMed Sethna C, Benchimol C, Hotchkiss H, Frank R, Infante L, Vento S, Trachtman H (2011) Treatment of recurrent focal segmental glomerulosclerosis in pediatric kidney transplant recipients: effect of rituximab. J Transplant. doi:10.​1155/​2011/​389542 PubMed
38.
Zurück zum Zitat Marks SD, McGraw M (2007) Does rituximab treat recurrent focal segmental glomerulosclerosis post-renal transplantation? Pediatr Nephrol 22:158–160PubMedCrossRef Marks SD, McGraw M (2007) Does rituximab treat recurrent focal segmental glomerulosclerosis post-renal transplantation? Pediatr Nephrol 22:158–160PubMedCrossRef
39.
Zurück zum Zitat Peters HP, van de Kar NC, Wetzels JF (2008) Rituximab in minimal change nephropathy and focal segmental glomerulosclerosis: report of four cases and review of the literature. Neth J Med 66:408–415PubMed Peters HP, van de Kar NC, Wetzels JF (2008) Rituximab in minimal change nephropathy and focal segmental glomerulosclerosis: report of four cases and review of the literature. Neth J Med 66:408–415PubMed
40.
Zurück zum Zitat Araya CE, Dharnidharka VR (2011) The factors that may predict response to rituximab therapy in recurrent focal segmental glomerulosclerosis: a systematic review. J Transplant. doi:10.1155/2011/374213 PubMed Araya CE, Dharnidharka VR (2011) The factors that may predict response to rituximab therapy in recurrent focal segmental glomerulosclerosis: a systematic review. J Transplant. doi:10.​1155/​2011/​374213 PubMed
41.
Zurück zum Zitat Kamei K, Ito S, Iijima K (2010) Severe respiratory adverse events associated with rituximab infusion. Pediatr Nephrol 25:1193PubMedCrossRef Kamei K, Ito S, Iijima K (2010) Severe respiratory adverse events associated with rituximab infusion. Pediatr Nephrol 25:1193PubMedCrossRef
42.
Zurück zum Zitat Vallet H, Houitte R, Azria A, Mariette X (2011) Cytomegalovirus colitis and hypo-IgG after rituximab therapy for rheumatoid arthritis. J Rheumatol 38:965–966PubMedCrossRef Vallet H, Houitte R, Azria A, Mariette X (2011) Cytomegalovirus colitis and hypo-IgG after rituximab therapy for rheumatoid arthritis. J Rheumatol 38:965–966PubMedCrossRef
43.
Zurück zum Zitat Vo KH, Waddell JA, Suda KJ (2011) Rapid development of infusion-related severe hypotension during rituximab therapy. Ann Pharmacother 45:e29PubMedCrossRef Vo KH, Waddell JA, Suda KJ (2011) Rapid development of infusion-related severe hypotension during rituximab therapy. Ann Pharmacother 45:e29PubMedCrossRef
44.
Zurück zum Zitat Bitzan M, Ouahed JD, Carpineta L, Bernard C, Bell LE (2010) Cryptogenic organizing pneumonia after rituximab therapy for presumed post-kidney transplant lymphoproliferative disease. Pediatr Nephrol 25:1163–1167PubMedCrossRef Bitzan M, Ouahed JD, Carpineta L, Bernard C, Bell LE (2010) Cryptogenic organizing pneumonia after rituximab therapy for presumed post-kidney transplant lymphoproliferative disease. Pediatr Nephrol 25:1163–1167PubMedCrossRef
45.
Zurück zum Zitat Bitzan M, Anselmo M, Carpineta L (2009) Rituximab (B-cell depleting antibody) associated lung injury (RALI): a pediatric case and systematic review of the literature. Pediatr Pulmonol 44:922–934PubMedCrossRef Bitzan M, Anselmo M, Carpineta L (2009) Rituximab (B-cell depleting antibody) associated lung injury (RALI): a pediatric case and systematic review of the literature. Pediatr Pulmonol 44:922–934PubMedCrossRef
46.
Zurück zum Zitat Chaumais MC, Garnier A, Chalard F, Peuchmaur M, Dauger S, Jacqz-Agrain E, Deschenes G (2009) Fatal pulmonary fibrosis after rituximab administration. Pediatr Nephrol 24:1753–1755PubMedCrossRef Chaumais MC, Garnier A, Chalard F, Peuchmaur M, Dauger S, Jacqz-Agrain E, Deschenes G (2009) Fatal pulmonary fibrosis after rituximab administration. Pediatr Nephrol 24:1753–1755PubMedCrossRef
Metadaten
Titel
Rituximab in post-transplant pediatric recurrent focal segmental glomerulosclerosis
verfasst von
Juhi Kumar
Ibrahim F. Shatat
Amy L. Skversky
Robert P. Woroniecki
Marcela Del Rio
Eduardo M. Perelstein
Valerie L. Johnson
Shefali Mahesh
Publikationsdatum
01.02.2013
Verlag
Springer-Verlag
Erschienen in
Pediatric Nephrology / Ausgabe 2/2013
Print ISSN: 0931-041X
Elektronische ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-012-2314-6

Weitere Artikel der Ausgabe 2/2013

Pediatric Nephrology 2/2013 Zur Ausgabe

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.